Differential effects of AMPK agonists on cell growth and metabolism

Oncogene

Volumn 34, Issue 28, 2015, Pages 3627-3639

  Vincent, E E ^a,b   Coelho, P P ^a,b   Blagih, J ^a,b   Griss, T ^a,b   Viollet, B ^c,d,e   Jones, R G ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c INSTITUT COCHIN   (France)

^d CNRS   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE; 6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ADENYLATE KINASE; AICA RIBONUCLEOTIDE; ANTIDIABETIC AGENT; GLUCOSE; LACTIC ACID; METFORMIN; PHENFORMIN; PYRONE DERIVATIVE; RIBONUCLEOTIDE; SALICYLATE SODIUM; THIOPHENE DERIVATIVE;

ANALOGS AND DERIVATIVES; ANIMAL; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; HCT116 CELL LINE; HEK293 CELL LINE; HUMAN; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ADENYLATE KINASE; AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GLUCOSE; HCT116 CELLS; HEK293 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; LACTIC ACID; METFORMIN; MICE; NEOPLASMS; PHENFORMIN; PYRONES; RIBONUCLEOTIDES; SODIUM SALICYLATE; THIOPHENES;

EID: 84942588417     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.301     Document Type: Article

References (64)

1. Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T, Neumann D. Dissecting the role of 5?-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem 2006; 281: 32207-32216.
2. Hardie DG. AMP-activated/SNF1 protein kinases: Conserved guardians of cellular energy. Nat Rev Mol Cell Biol 2007; 8: 774-785.
3. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 2004; 29: 18-24.
4. Hardie DG. AMP-activated protein kinase: A cellular energy sensor with a key role in metabolic disorders and in cancer. Biochem Soc Trans 2011; 39: 1-13.
5. Davies SP, Sim AT, Hardie DG. Location and function of three sites phosphorylated on rat acetyl-CoA carboxylase by the AMP-activated protein kinase. Eur J Biochem 1990; 187: 183-190.
6. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, Vasquez DS et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30: 214-226.
7. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003; 115: 577-590.
8. Imamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H. Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 2001; 287: 562-567.
9. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 2005; 18: 283-293.
10. Shackelford DB, Shaw RJ. The LKB1-AMPK pathway: Metabolism and growth control in tumour suppression. Nat Rev Cancer 2009; 9: 563-575.
11. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP et al. Complexes between the LKB1 tumor suppressor, STRADalpha/beta and MO25alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2003; 2: 28.
12. Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu Rev Biochem 2006; 75: 137-163.
13. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gittelsohn AM, Booker SV et al. Increased risk of cancer in the Peutz-Jeghers syndrome. New Engl J Med 1987; 316: 1511-1514.
14. Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006; 12: 3209-3215.
15. Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 2007; 26: 7825-7832.
16. Dupuy F, Griss T, Blagih J, Bridon G, Avizonis D, Ling C et al. LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. Cancer Metab 2013; 1: 18.
17. Shackelford DB, Vasquez DS, Corbeil J, Wu S, Leblanc M, Wu CL et al. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci USA 2009; 106: 11137-11142.
18. Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 2013; 17: 113-124.
19. Kim I, He YY. Targeting the AMP-activated protein kinase for cancer prevention and therapy. Front Oncol 2013; 3: 175.
20. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348(Pt 3): 607-614.
21. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000; 275: 223-228.
22. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305.
23. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B et al. Metformin and cancer risk in diabetic patients: A systematic review and metaanalysis. Cancer Prev Res (Phila) 2010; 3: 1451-1461.
24. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745-6752.
25. Wu N, Gu C, Gu H, Hu H, Han Y, Li Q. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. Neoplasma 2011; 58: 482-490.
26. Appleyard MV, Murray KE, Coates PJ, Wullschleger S, Bray SE, Kernohan NM et al. Phenformin as prophylaxis and therapy in breast cancer xenografts. Br J Cancer 2012; 106: 1117-1122.
27. Pollak M. Potential applications for biguanides in oncology. J Clin Invest 2013; 123: 3693-3700.
28. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-aminoimidazole-4-carboxamide ribonucleoside A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 1995; 229: 558-565.
29. El-Masry OS, Brown BL, Dobson PR. Effects of activation of AMPK on human breast cancer cell lines with different genetic backgrounds. Oncol Lett 2012; 3: 224-228.
30. Rosilio C, Lounnas N, Nebout M, Imbert V, Hagenbeek T, Spits H et al. The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells. Cancer Lett 2013; 336: 114-126.
31. Cool B, Zinker B, Chiou W, Kifle L, Cao N, Perham M et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 2006; 3: 403-416.
32. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2013; 336: 918-922.
33. Elder DJ, Hague A, Hicks DJ, Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: Enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma relative to adenoma cell lines. Cancer Res 1996; 56: 2273-2276.
34. Hardie DG. AMPK: A target for drugs and natural products with effects on both diabetes and cancer. Diabetes 2013; 62: 2164-2172.
35. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007; 9: 218-224.
36. Bungard D, Fuerth BJ, Zeng PY, Faubert B, Maas NL, Viollet B et al. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science 2010; 329: 1201-1205.
37. Zannella VE, Cojocari D, Hilgendorf S, Vellanki RN, Chung S, Wouters BG et al. AMPK regulates metabolism and survival in response to ionizing radiation. Radiother Oncol 2011; 99: 293-299.
38. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
39. Liang J, Mills G. AMPK: A contextual oncogene or tumor suppressor? Cancer Res 2013; 73: 2929-2935.
40. Pachman L, Esterly N, Peterson R. The effect of salicylate on the metabolism of normal and stimulated human lymphocytes in vitro. J Clin Invest 1971; 50: 226-230.
41. Brody T. Action of sodium salicylate and related compounds on tissue metabolism in vitro. J Pharmacol Exp Ther 1956; 117: 39-51.
42. Nicholls DG. Spare respiratory capacity, oxidative stress and excitotoxicity. Biochem Soc Trans 2009; 37: 1385-1388.
43. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM et al. Calmodulindependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2005; 2: 9-19.
44. Goransson O, McBride A, Hawley SA, Ross FA, Shpiro N, Foretz M et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 2007; 282: 32549-32560.
45. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010; 11: 390-401.
46. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66: 10269-10273.
47. Dykens JA, Jamieson J, Marroquin L, Nadanaciva S, Billis PA, Will Y. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 2008; 233: 203-210.
48. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422-1431.
49. Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G et al. A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med 2014; 6: 519-538.
50. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008; 412: 211-221.
51. Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013; 23: 143-158.
52. Faubert B, Vincent EE, Poffenberger MC, Jones RG. The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator. Cancer letters 2014.
53. Garber K. Energy deregulation: Licensing tumors to grow. Science 2006; 312: 1158-1159.
54. Guigas B, Bertrand L, Taleux N, Foretz M, Wiernsperger N, Vertommen D et al. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinaseindependent effect on glucokinase translocation. Diabetes 2006; 55: 865-874.
55. Vincent MF, Bontemps F, Van Den Berghe G. Inhibition of glycolysis by 5-amino-4-imidazolecarboxamide riboside in isolated rat hepatocytes. Biochem J 1992; 281 (Pt 1): 267-272.
56. Morita M, Gravel SP, Chenard V, Sikstrom K, Zheng L, Alain T et al. mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab 2013; 18: 698-711.
57. Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochem J 2011; 435: 297-312.
58. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012; 485: 661-665.
59. Godlewski J, Nowicki MO, Bronisz A, Nuovo G, Palatini J, De Lay M et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell 2010; 37: 620-632.
60. Chhipa RR, Wu Y, Mohler JL, Ip C. Survival advantage of AMPK activation to androgen-independent prostate cancer cells during energy stress. Cell Signal 2010; 22: 1554-1561.
61. Laderoute KR, Amin K, Calaoagan JM, Knapp M, Le T, Orduna J et al. 5?-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 2006; 26: 5336-5347.
62. Crissman HA, Steinkamp JA. simultaneous measurement of DNA, protein, and cell volume in single cells from large mammalian cell populations. J Cell Biol 1973; 59: 766-771.
63. Vincent EE, Elder DJ, Curwen J, Kilgour E, Hers I, Tavare JM. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor. PLoS ONE 2013; 8: E66963.
64. Faubert B, Vincent EE, Griss T, Samborska B, Izreig S, Svensson RU et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1alpha. Proc Natl Acad Sci USA 2014; 111: 2554-2559.